Tempest Reports Inducement Grants Under Nasdaq Listing Rule

BRISBANE, Calif., May 19, 2023 -- Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms,... | May 19, 2023

Related Keywords

California , United States , Brisbane , Queensland , Australia , Sylvia Wheeler , Aljanae Reynolds , Tempest Therapeutics Inc , Nasdaq , Compensation Committee , Nasdaq Listing Rule , Incentive Plan , Tempest Therapeutics , Nc Stock Exchange , News , Information , Press Release , Bay , 023 , Tempest , Ncology , Company , Developing , Herapeutics , Hat , Ombine , Moth , Argeted , Nd Tpst Us87978u1088 ,